Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of atypicalemerging pneumonia. The clinical spectrum varies from an asymptomatic or mild illness toa serious illness with a high risk of mortality. The most severely affected patients (5%)present an acute respiratory distress syndrome (ARDS), requiring assistance withmechanical ventilation in intensive care.In 2003, persistent lung damage was observed in a third of patients in a Singaporeancohort one year after SARS-CoV infection. A Chinese study showed that 27.3% of theirSARS-CoV patients presented a decreased carbon monoxide diffusion (DLCO) and 21.5% ofpulmonary fibrosis lesions.Due to the very recent emergence of SARS-CoV-2, no data is currently available oflong-term outcome of these patients. However, recent publications including short-term CTmonitoring suggest the genesis of fibrotic pulmonary parenchymal sequelae.In view of these data, the investigators can fear the occurrence of pulmonary sequelae inpatients infected with SARS-CoV-2. It is therefore essential to evaluate the evolution ofthe respiratory status of the most severe patients who have had a stay in intensive carewith respiratory assistance.
Diagnostic Test: Pulmonary function testing
D0: date of first symptoms of SARS-COV-2
M3: D0 + 3 months
- Blood test
- Blood gases
- Clinical examination
- CT Scan
- Pulmonary function testing (PFT)
- 6-minute walk test (6MWT)
- MOS SF-36 Questionnaire
- HADS scale
- Ventilatory polygraphy
M6: D0 + 6 months
- Clinical examination
- PFT
- 6MWT
- MOS SF-36 Questionnaire
- HADS scale
M12: D0 + 12 months
- Blood test
- Blood gases
- Clinical examination
- CT Scan (If anomaly found at M3)
- PFT
- Pulmonary Exercise Stress Test
- 6MWT
- MOS SF-36 Questionnaire
- HADS scale
Subsequent follow-up will be performed only in patients with an alteration defined by a M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months - Clinical examination - PFT - 6MWT - MOS SF-36 Questionnaire - HADS scale
DLCO
Other Name: CT Scan,Six minute walk test,Pulmonary Exercise Stress Test,Blood gases,Ventilatory polygraphy,Questionnaires: HADS and MOS SF-36,Blood Test
Inclusion Criteria:
- Patient infected by SARS-CoV-2 (diagnosed by RT-PCR and / or typical CT imaging)
- Patient hospitalized in the intensive care units of Besançon or Dijon hospitals for
severe SARS-CoV-2 pneumonia
- Postmenopausal woman for at least 24 months or surgically sterilized, or, for woman
of childbearing age, use of an effective method of contraception
- Signature of informed consent to participate indicating that the subject has
understood the purpose and the procedures required by the study and that he agrees
to participate in the study.
- Affiliation to a French social security system .
Exclusion Criteria:
- Chronic respiratory failure under long-term oxygen therapy
- Known diffuse invasive pneumonia
- Life expectancy estimated at less than one year by the doctor
- Legal incapacity or limited legal capacity
- History of psychiatric illness, intellectual disability, lack of motivation or other
conditions that may limit the understanding of informed consent
- Subject unlikely to cooperate in the study and / or weak cooperation anticipated by
the investigator
- Subject without health insurance
- Pregnant and / or lactating woman
- Subject being in the exclusion period of another study or foreseen by the "national
file of the volunteers".
CHU Besançon
Besançon, Franche-Comté, France